Non-invasive prenatal testing (NIPT) is a modern technology using sequencing of free fetal (amniotic) DNA circulating in maternal blood for an accurate detection of chromosomal abnormalities in the fetus as early as from week 10 of pregnancy. This new method is very accurate and safe for the fetus. The Clarigo (CE IVD) diagnostic kit, used in our laboratory, is designed for non-invasive testing of the most common numerical variations of chromosomes 13 (Patau syndrome), 18 (Edwards syndrome) and 21 (Down syndrome) and to determine the sex of the fetus. The test can determine the risk for defects of sexual chromosomes. Determining the risk of sex chromosome defects does not preclude the possibility of sexual chromosome abnormalities in the fetus. The positive detection should be verified by invasive testing (e.g. amniocentesis or chorionic villus sampling).